EU Orphan Medicinal Products: Regulatory Framework, Designation Criteria, EMA Procedures, Market Exclusivity and Derogations, Similarity and Clinical Superiority, Off-label Implications, Key Case Law and Proposed Reforms
Published by a
LexisNexis EU Law expert
Practice notes
Orphan medicinal products (OMPs)
Orphan medicinal products (OMPs) are medicines intended to prevent, diagnose or treat rare medical disorders and conditions. Because patient numbers are extremely small, and in the absence of incentives, pharmaceutical firms may doubt whether sales would ever cover the research and development (R&D) costs of creating medical products to diagnose, prevent and treat such rare diseases. In EU law, ‘rare’ means affecting fewer than five in 10,000 people across the EU. Yet most rare diseases impact fewer than one in 100,000 individuals. Although each rare disease is uncommon, they carry notable public health significance and enduring relevance. It is estimated there are more than 6,000 rare diseases; thus, while each is infrequent, together they account for a substantial patient population, in aggregate roughly one in every 12 people in the EU (all rare diseases combined). Without incentives, developing and marketing OMPs is often not commercially feasible for pharmaceutical companies, and only about 5% of rare diseases currently have an authorised treatment option available at present. Guided by the principle that people with rare diseases should access medicines that meet the same standards of quality, safety and efficacy as other patients and communities, the EU introduced, at European level,...
To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.
Web page updated on 21/05/2026
Popular documents
When evaluating a general damages claim, the practitioner ought initially to refer to the Judicial College Guidelines (JCG)...
This Practice Note This Practice Note reviews mechanisms used in settling litigation. A Tomlin order consists of a consent order paired with a schedule. It operates to stay proceedings on terms that have been agreed. The provisions contained in the schedule may remain confidential. This Practice Note describes the scope of confidentiality attaching to the schedule and sets out how it differs from a standard consent order. Sample wording for a Tomlin order is included, alongside links to precedents, as well as guidance on court approval. It also addresses varying, setting aside and enforcing a Tomlin order, including the considerations the court will take into account when handling applications for each. Further guidance is provided on interpreting and applying the relevant provisions of the CPR; however, some courts and divisions impose very specific requirements for both drafting and approval, and for approaching the schedule and confidentiality issues. Accordingly, you must consider the particular rules and court guide provisions in the forum where your claim is proceeding when drawing up the Tomlin order...
Date [ date ] Parties [ name of Landlord ] [ of OR incorporated in England and Wales (company registration number [ number ]) with its registered office at ] [ address ] (Landlord) [ name of Tenant ] [ of OR incorporated in England and Wales (company registration number [ number ]) with its registered office at ] [ address ] (Tenant) [ [ name of Guarantor ] [ of OR incorporated in England and Wales (company registration number [ number ]) with its registered office at ] [ address ] (Guarantor) ] [ [ name of Mortgagee ] [ of OR incorporated in England and Wales (company registration number [ number ]) with its registered office at ] [ address ] (Mortgagee) ] Definitions Within this Deed, the terms below shall be interpreted as follows: [ Annual Rent • the annual sum reserved under the Lease; ] [ Insurance Rent • the Tenant’s share of the Landlord’s costs of insuring the Property (as set out in the Lease); ] Lease • the lease of the Property dated [ date ], entered into between (1) [ the Landlord OR [ name ...
I, [ name ], of [ address ], solemnly and sincerely state that: [ Matters to be verified, set out in numbered paragraphs ] I make this solemn statement in good conscience, believing it to be true, and pursuant to the provisions of the Statutory Declarations Act 1835. DECLARED at [ details ] this [ day ] day of [ month and year ] Before me ................................................................................ [ signature of the person before whom the declaration is made ] A [ commissioner for oaths OR [ solicitor OR [ insert other qualification ] ] authorised to administer oaths ]...
Discover more from LexisNexis
